Cranial bone marrow-derived monocytes promote neuroinflammation in chronic traumatic brain injury.

Cranial bone marrow-derived monocytes drive neuroinflammation in chronic traumatic brain injury, with 40% reduction in neurofilament light chain levels after fenofibrate treatment.

• Why it matters: Understanding the mechanisms behind long-term neurological decline in cTBI, especially in older patients, is crucial for developing targeted therapies to mitigate chronic neuroinflammation and improve outcomes.
• What they did: Researchers combined clinical samples, cell-tracing, multiomics profiling, animal models, and a clinical trial involving 40 older cTBI patients to investigate immune cell contributions and test fenofibrate’s effects on inflammation and cognition.
• The result: Findings reveal that CBM-derived monocytes exacerbate neuroinflammation and neurological deficits, and activating PPARα with fenofibrate reduces inflammatory cell infiltration and improves cognitive function, suggesting a promising therapeutic approach.